Characterization of BM-MSC. by Chen Lu (135200)

Subjects:

Pretreatment of BM-MSCs improves the survival rate and incidence of DCS. by Chen Lu (135200)

Subjects:

Utilization of anticoagulants at eight hospitals from 2019 to 2023. by Wei Luo (80175)

Subjects:

The ANCOVA and Post_hoc results. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

The demographical and clinical characteristics of subjects at baseline. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

CONSORT flowchart. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Inpatient utilization of anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

Indications for warfarin prescription in outpatients and inpatients in 2023. by Wei Luo (80175)

Subjects:

Time to stabilization in the mediolateral direction. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Outpatient utilization of anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

Participant’s data including characteristics and primary outcome measurement. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Effects of BM-MSCs on different types of lung cell death in different group. by Chen Lu (135200)

Subjects:

Time to stabilization in the vertical direction. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

DDC for four anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

A schematic representation of how BM-MSCs reduce inflammation, oxidative stress, and cell death to alleviate decompression induced acute lung injury. by Chen Lu (135200)

Subjects:

Raw Data. by Chen Lu (135200)

Subjects:

Utilization of anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

The description of games. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

The expenditure on anticoagulants in the period of 2019-2023(million CNY). by Wei Luo (80175)

Subjects:

The description of balance training. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects: